Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions

doi:10.3748/wjg.v13.i36.4891

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 36

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2214)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

234

HTML

1502

Figures (1-3)

266

Tables (1-2)

212

Sum=2214

Sep 28, 2007 (publication date) through Nov 5, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Sep 28, 2007; 13(36): 4891-4896
Published online Sep 28, 2007. doi: 10.3748/wjg.v13.i36.4891

Full Size Figure Download Figure

Figure 3 HCC image. A: The lesion appears hyperintense on the pre-contrast T2WI FSE image, but is not clearly delineated; B: The lesion is markedly enhanced during the hepatic arterial phase; C: The lesion appears hypointence during the portal venous phase, but is not clearly delineated; D: The main lesion and satellite nodules are clearly delineated from the surrounding hypointense liver parenchyma on the ferucarbotran-enhanced T2WI image during the accumulation phase.

Citation: Cheng WZ, Zeng MS, Yan FH, Rao SX, Shen JZ, Chen CZ, Zhang SJ, Shi WB. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol 2007; 13(36): 4891-4896
URL: https://www.wjgnet.com/1007-9327/full/v13/i36/4891.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i36.4891